UNC926 hydrochloride

CAS No. 1782573-49-2

UNC926 hydrochloride( —— )

Catalog No. M23797 CAS No. 1782573-49-2

UNC926 hydrochloride is a?methyl-lysine (Kme) reader domain?inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 272 In Stock
10MG 408 In Stock
25MG 672 In Stock
50MG 945 In Stock
100MG 1278 In Stock
500MG 2547 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    UNC926 hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    UNC926 hydrochloride is a?methyl-lysine (Kme) reader domain?inhibitor.
  • Description
    UNC926 hydrochloride is a?methyl-lysine (Kme) reader domain?inhibitor.
  • In Vitro
    UNC926 also exhibits a low micromolar affinity for the close homolog, L3MBTL3 ( IC50 of 3.2 μM), with a decrease in affinity for the other MBT domains and no binding to CBX7.UNC926 (1-25 μM) inhibits binding of the 3xMBT domain to H4K20me1.UNC926 inhibits the association of L3MBTL13xMBT with the appropriate histonepeptides in a dose-dependent manner. UNC926 does not have an effect on the binding of 53BP1 to H4K20me1, demonstrating specificity of UNC926 for L3MBTL1 over 53BP1.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    L3MBTL1|L3MBTL3|L3MBTL4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1782573-49-2
  • Formula Weight
    373.72
  • Molecular Formula
    C16H22BrClN2O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:150 mg/mL?(444.77 mM)
  • SMILES
    O=C(C1=CC=CC(Br)=C1)N2CCC(N3CCCC3)CC2.[H]Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Herold JM, et al. Structure-activity relationships of methyl-lysine reader antagonists. MedChemComm. 2012;3(45):45-51.
molnova catalog
related products
  • Pocenbrodib

    Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.

  • GSK620

    GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.

  • dCBP-1

    dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.